nach oben

Inflammation Research

Erschienen in:

28.02.2021 | COVID-19 | Review Zur Zeit gratis

COVID-19 illness and autoimmune diseases: recent insights

verfasst von: Juan Li, Hong-Hui Liu, Xiao-Dong Yin, Cheng-Cheng Li, Jing Wang

Erschienen in: Inflammation Research | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this review is to explore whether patients with autoimmune diseases (AIDs) were at high risk of infection during the COVID-19 epidemic and how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic affected immune system.

Methods

A systematic literature search was performed using the foreign databases (NCBI, web of science, EBSCO, ELSEVIER ScienceDirect) and Chinese databases (WanFang, CNKI (China National Knowledge Infrastructure), VIP, CBM) to locate all relevant publications (up to January 10, 2021). The search strategies used Medical Search Headings (MeSH) headings and keywords for “COVID-19” or “SARS-CoV-2” or “coronavirus” and “autoimmune disease”.

Results

This review evaluates the effect of SARS-CoV-2 on the immune system through ACE-2 receptor binding as the main pathway for cell attachment and invasion. It is speculated that SARS-COV-2 infection can activate lymphocytes and inflammatory response, which may play a role in the clinical onset of AIDs and also patients were treated with immunomodulatory drugs during COVID-19 outbreak. Preliminary studies suggested that the risk of developing severe forms of COVID-19 in patients with AIDs treated with immunomodulators or biologics might not increase. A large number of samples are needed for further verification, leading to an excessive immune response to external stimuli.

Conclusion

The relationship between autoimmune diseases and SARS-CoV-2 infection is complex. During the COVID-19 epidemic, individualized interventions for AIDs should be provided such as Internet-based service.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2019;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20) (published correction appears in Lancet. 2020 Jan 30).CrossRef

World Health Organization. Coronavirus disease (COVID-19) pandemic. who.int/ emergencies/diseases/novel-coronavirus-2019.

Flahault A. COVID-19 cacophony: is there any orchestra conductor? Lancet. 2020;395(10229):1037. https://doi.org/10.1016/S0140-6736(20)30491-8.CrossRefPubMedPubMedCentral

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine: united states, December 2020. MMWR Morb Mortal Wkly Rep. 2020;69(50):1922–4.CrossRefPubMedPubMedCentral

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. The advisory committee on immunization practices’ interim recommendation for use of moderna COVID-19 Vaccine: united states, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69(5152):1653–6. https://doi.org/10.15585/mmwr.mm695152e1.CrossRefPubMed

Karagianni P, Tzioufas AG. Epigenetic perspectives on systemic autoimmune disease. J Autoimmun. 2019;104:102315. https://doi.org/10.1016/j.jaut.2019.102315.CrossRefPubMed

Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020;19(5):102523. https://doi.org/10.1016/j.autrev.2020.102523.CrossRefPubMedPubMedCentral

Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza- Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(6):839–40. https://doi.org/10.1136/annrheumdis-2020-217322.CrossRefPubMed

D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases (SARDs) compared to the general population: a us multi-center comparative cohort study. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41619.10.1002/art.41619.CrossRef

10.

Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524. https://doi.org/10.1016/j.autrev.2020.102524.CrossRefPubMedPubMedCentral

11.

Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19(7):102575. https://doi.org/10.1016/j.autrev.2020.102575.CrossRefPubMedPubMedCentral

12.

Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: a cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. https://doi.org/10.1016/j.jaut.2020.102502.CrossRefPubMedPubMedCentral

13.

Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41388.CrossRefPubMedPubMedCentral

14.

Yazdany J, Kim AHJ. Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med. 2020;172(11):754–5. https://doi.org/10.7326/M20-1334.CrossRefPubMed

15.

Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055–62. https://doi.org/10.1007/s10067-020-05073-9.CrossRefPubMed

16.

Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19 Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19(7):102569. https://doi.org/10.1016/j.autrev.2020 (102569).CrossRefPubMedPubMedCentral

17.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1–9. https://doi.org/10.12932/AP-200220-0772.CrossRefPubMed

18.

Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345. https://doi.org/10.1016/j.mehy.2020.CrossRefPubMedPubMedCentral

19.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS- CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–80. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

20.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. Nature. 2020;579:270–3. https://doi.org/10.1038/s41586-020-2012-7.CrossRefPubMedPubMedCentral

21.

Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568–76. https://doi.org/10.1002/jmv.25748.CrossRefPubMed

22.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180(7):1–11. https://doi.org/10.1001/jamainternmed.2020.0994.CrossRef

23.

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-united states, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–6. https://doi.org/10.15585/mmwr.mm6912e2.CrossRefPubMedCentral

24.

Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020;83(3):217–20. https://doi.org/10.1097/JCMA.0000000000000270.CrossRefPubMedPubMedCentral

25.

Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccinesfor novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313–24. https://doi.org/10.4014/jmb.2003.03011.CrossRefPubMed

26.

Netea MG, van der Meer JW, van Crevel R. BCG vaccination in healthcare providers and the protection against COVID-19. J Clin Invest. 2020. https://doi.org/10.1172/JCI145545.CrossRefPubMedPubMedCentral

27.

Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open. 2020;3(12):e2029058. https://doi.org/10.1001/jamanetworkopen.2020.29058.CrossRefPubMedPubMedCentral

28.

Shamshirian A, Hessami A, Heydari K, Navaei RA, Ebrahimzadeh MA, Yip GW, et al. the role of hydroxychloroquine in COVID-19: a systematic review and meta-analysis. Ann Acad Med Singap. 2020;49(10):789–800.CrossRefPubMed

29.

Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493–502. https://doi.org/10.1001/jama.2020.8630.CrossRefPubMedPubMedCentral

30.

Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-1. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2021801.10.1056/NEJMoa2021801.CrossRefPubMedPubMedCentral

31.

Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial. Ann Intern Med. 2020. https://doi.org/10.7326/M20-6519.10.7326/M20-6519.CrossRefPubMedPubMedCentral

32.

Chen CP, Lin YC, Chen TC, Tseng TY, Wong HL, Kuo CY, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS ONE. 2020;15(12):e0242763. https://doi.org/10.1371/journal.pone.0242763 (eCollection 2020).CrossRefPubMedPubMedCentral

33.

Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed antiviral drugs for covid-19: interim WHO solidarity trial results. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2023184.CrossRefPubMedPubMedCentral

34.

Cantini F, Goletti D, Petrone L, Najafi Fard S, Niccoli L, Foti R. Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs. 2020;80(18):1929–46. https://doi.org/10.1007/s40265-020-01421-w.CrossRefPubMedPubMedCentral

35.

Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–16. https://doi.org/10.1172/JCI141772.CrossRefPubMedPubMedCentral

36.

Rodriguez-Garcia JL, Sanchez-Nievas G, Arevalo-Serrano J, Garcia-Gomez C, Jimenez-Vizuete JM, Martinez-Alfaro E. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatol (Oxf). 2020. https://doi.org/10.1093/rheumatology/keaa587.CrossRef

37.

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2031994.10.1056/NEJMoa2031994.CrossRefPubMedPubMedCentral

38.

Dai W, Wu J, Li T, Shen J, Pang R, Luo T, et al. Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan. China J Med Virol. 2020. https://doi.org/10.1002/jmv.26712.10.1002/jmv.26712.CrossRefPubMed

39.

Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis. 2020;S1201–9712(20):32513–23. https://doi.org/10.1016/j.ijid.2020.11.198.CrossRef

40.

Khalili M, Karamouzian M, Nasiri N, Javadi S, Mirzazadeh A, Sharifi H. Epidemiological characteristics of COVID-19: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e130. https://doi.org/10.1017/S0950268820001430.CrossRefPubMed

41.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102537.CrossRefPubMedPubMedCentral

42.

Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treat- ment options. Clin Immunol. 2020;215:108448. https://doi.org/10.1016/j.clim.2020.108448.CrossRefPubMedPubMedCentral

43.

Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from wuhan: a retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–9. https://doi.org/10.1164/rccm.202003-0543OC.CrossRefPubMedPubMedCentral

44.

Market M, Angka L, Martel AB, Bastin D, Olanubi O, Tennakoon G, et al. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front Immunol. 2020;11:1512. https://doi.org/10.3389/fimmu.2020.01512.CrossRefPubMedPubMedCentral

45.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26:842–4. https://doi.org/10.1038/s41591-020-0901-9.CrossRefPubMed

46.

Demaria O, Carvelli J, Batista L, Thibult ML, Morel A, André P, et al. Identification of druggable inhibitory immune checkpoints on natural killer cells in COVID-19. Cell Mol Immunol. 2020. https://doi.org/10.1038/s41423-020-0493-9.CrossRefPubMed

47.

Jiang M, Guo Y, Luo Q, Huang Z, Zhao R, Liu S, et al. T-Cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis. 2020;222(2):198–202. https://doi.org/10.1093/infdis/jiaa252.CrossRefPubMed

48.

Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, et al. The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: a sentinel? Clin Chim Acta. 2020;508:122–9. https://doi.org/10.1016/j.cca.2020.05.027.CrossRefPubMedPubMedCentral

49.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–5. https://doi.org/10.1038/s41423-020-0402-2.CrossRefPubMedPubMedCentral

50.

Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643–75. https://doi.org/10.1146/annurev-immunol-032414-112220.CrossRefPubMed

51.

Park MD. Macrophages: a Trojan horse in COVID-19? Nat Rev Immunol. 2020;20(6):351. https://doi.org/10.1038/s41577-020-0317-2.CrossRefPubMed

52.

Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020. https://doi.org/10.1038/s41586-020-2312-y.10.1038/s41586-020-2312-y.CrossRefPubMedPubMedCentral

53.

Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700–4. https://doi.org/10.1016/j.jtho.2020.02.010.CrossRefPubMedPubMedCentral

54.

Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, et al. Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients. EBioMedicine. 2020;57:102833. https://doi.org/10.1016/j.ebiom.2020.102833.CrossRefPubMedPubMedCentral

55.

Chang YS, Ko BH, Ju JC, Chang HH, Huang SH, Lin CW. SARS unique domain (SUD) of Severe acute respiratory syndrome coronavirus induces NLRP3 Inflammasome-dependent CXCL10 -mediated pulmonary inflammation. Int J Mol Sci. 2020;21(9):3179. https://doi.org/10.3390/ijms21093179.CrossRefPubMedCentral

56.

Pagliaro P. Is macrophages heterogeneity important in determining COVID-19 lethality? Med Hypotheses. 2020;143:110073. https://doi.org/10.1016/j.mehy.2020.110073.CrossRefPubMedPubMedCentral

57.

Roney K. Bone marrow-derived dendritic cells. Methods Mol Biol. 2019;1960:57–62. https://doi.org/10.1007/978-1-4939-9167-9_4.CrossRefPubMed

58.

Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 2006;311:17–58. https://doi.org/10.1007/3-540-32636-7_2.CrossRefPubMed

59.

Sanchez-Cerrillo I, Landete P, Aldave B, Sanchez-Alonso S, Sanchez-Azofra A, Marcos-Jimenez A, et al. Differential redistribution of activated monocyte and dendritic cell subsets to the lung associates with severity of COVID-19. Medrxiv. 2020. https://doi.org/10.1101/2020.05.13.20100925 (Preprint 2020;2020. 05.13. 20100925).CrossRefPubMedPubMedCentral

60.

Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC, et al. Attenuated interferon and pro-inflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa356.CrossRefPubMedPubMedCentral

61.

Wei LL, Wang WJ, Chen DX, Xu B. Dysregulation of the immune response affects the outcome of critical COVID-19 patients. J Med Virol. 2020. https://doi.org/10.1002/jmv.26181.10.1002/jmv.26181.CrossRefPubMedPubMedCentral

62.

Mitchell AJ, Roediger B, Weninger W. Monocyte homeostasis and the plasticity of inflammatory monocytes. Cell Immunol. 2014;291(1–2):22–31. https://doi.org/10.1016/j.cellimm.2014.05.010.CrossRefPubMed

63.

Peng J, Qi D, Yuan G, Deng X, Mei Y, Feng L, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): A multicenter, cross-sectional study. J Clin Lab Anal. 2019;2020:e23475. https://doi.org/10.1002/jcla.23475.CrossRef

64.

Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection. Cytometry A. 2020. https://doi.org/10.1002/cyto.a.24188.10.1002/cyto.a.24188.CrossRefPubMedPubMedCentral

65.

Ognibene A, Lorubbio M, Magliocca P, Tripodo E, Vaggelli G, Iannelli G, et al. Elevated monocyte distribution width in COVID-19 patients: the contribution of the novel sepsis indicator. Clin Chim Acta. 2020;509:22–4. https://doi.org/10.1016/j.cca.2020.06.002.CrossRefPubMedPubMedCentral

66.

Zeng F, Li L, Zeng J, Deng Y, Huang H, Chen B, et al. Can we predict the severity of coronavirus disease 2019 with a routine blood test? Pol Arch Intern Med. 2020;130(5):400–6. https://doi.org/10.20452/pamw.15331.CrossRefPubMed

67.

Pence BD. Severe COVID-19 and aging: are monocytes the key? Geroscience. 2020. https://doi.org/10.1007/s11357-020-00213-0.CrossRefPubMedPubMedCentral

68.

Xiong X, Chua GT, Chi S, Kwan MYW, Wong WHS, Zhou A, et al. Haematological and immunological data of Chinese children infected with coronavirus disease 2019. Data Brief. 2020;31:105953. https://doi.org/10.1016/j.dib.2020.105953.CrossRefPubMedPubMedCentral

69.

Schönrich G, Raftery MJ. Neutrophil extracellular traps go viral. Front Immunol. 2016;7:366. https://doi.org/10.3389/fimmu.2016.00366.CrossRefPubMedPubMedCentral

70.

Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018;18(2):134–47. https://doi.org/10.1038/nri.2017.105.CrossRefPubMed

71.

Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular histones are major mediators of death in sepsis. Nat Med. 2009;15(11):1318–21. https://doi.org/10.1038/nm.2053.CrossRefPubMedPubMedCentral

72.

Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(8):1777–83. https://doi.org/10.3389/fimmu.2018.00288.CrossRefPubMedPubMedCentral

73.

Zhou Y, Guo S, He Y, Zuo Q, Liu D, Xiao M, et al. COVID-19 is distinct from SARS-CoV-2-negative community-acquired pneumonia. Front Cell Infect Microbiol. 2020;10:322. https://doi.org/10.3389/fcimb.2020.00322.CrossRefPubMedPubMedCentral

74.

Xia XY, Wu J, Liu HL, Xia H, Jia B, Huang WX. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. J Clin Virol. 2020;127:104360. https://doi.org/10.1016/j.jcv.2020.104360.CrossRefPubMedPubMedCentral

75.

Wu H, Zhu H, Yuan C, Yao C, Luo W, Shen X, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020;3(6):e2010895. https://doi.org/10.1001/jamanetworkopen.2020.10895.CrossRefPubMedPubMedCentral

76.

Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18(1):206. https://doi.org/10.1186/s12967-020-02374-0.CrossRefPubMedPubMedCentral

77.

Xia X, Wen M, Zhan S, He J, Chen W. An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(3):333–6. https://doi.org/10.12122/j.issn.1673-4254.2020.03.06.CrossRefPubMed

78.

Wang H, Zhang Y, Mo P, Liu J, Wang H, Wang F, et al. Neutrophil to CD4⁺ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19. Int Immunopharmacol. 2020;85:106683. https://doi.org/10.1016/j.intimp.2020.106683.CrossRefPubMedPubMedCentral

79.

Didangelos A. COVID-19 Hyperinflammation: What about Neutrophils? mSphere. 2020;5(3):e00367-e420. https://doi.org/10.1128/mSphere.00367-20.CrossRefPubMedPubMedCentral

80.

Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. https://doi.org/10.1172/jci.insight.138999.CrossRefPubMedCentral

81.

Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. https://doi.org/10.1084/jem.20200652.CrossRefPubMedPubMedCentral

82.

Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. Int J Mol Sci. 2019;20(17):4241. https://doi.org/10.3390/ijms20174241 (Published 2019 Aug 30).CrossRefPubMedCentral

83.

Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–32. https://doi.org/10.1016/j.ijid.2020.09.016.CrossRefPubMedPubMedCentral

84.

Conti P, Caraffa A, Tetè G, Gallenga CE, Ross R, Kritas SK, et al. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J Biol Regul Homeost Agents. 2020;34(5):1629–32. https://doi.org/10.23812/20-2EDIT.CrossRefPubMed

85.

Theoharides TC. Potential association of mast cells with COVID-19. Ann Allergy Asthma Immunol. 2020;S1081–1206(20):31165. https://doi.org/10.1016/j.anai.2020.11.003.CrossRef

86.

Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen JL. Host immune response to influenza a virus infection. Front Immunol. 2018;9:320. https://doi.org/10.3389/fimmu.2018.00320.CrossRefPubMedPubMedCentral

87.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. https://doi.org/10.1172/JCI137244.CrossRefPubMedPubMedCentral

88.

Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.CrossRefPubMedPubMedCentral

89.

Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217(6):e20200678. https://doi.org/10.1084/jem.20200678.CrossRefPubMedPubMedCentral

90.

Liu B, Han JY, Cheng XH, Yu L, Zhang L, Wang W, et al. Persistent SARS-CoV-2 presence is companied with defects in adaptive immune system in non-severe COVID-19 patients. medRxiv. 2020. https://doi.org/10.1101/2020.03.26.20044768 (Preprint).CrossRefPubMedPubMedCentral

91.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–2. https://doi.org/10.1016/S2213-2600(20)30076-X.CrossRefPubMedPubMedCentral

92.

Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2 -specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020. https://doi.org/10.1038/s41586-020-2550-z.10.1038/s41586-020-2550-z.CrossRefPubMed

93.

Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971-977.e3. https://doi.org/10.1016/j.immuni.2020.04.023.CrossRefPubMedPubMedCentral

94.

He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune status in COVID-19 pneumonia. J Clin Virol. 2020;127:104361. https://doi.org/10.1016/j.jcv.2020.104361.CrossRefPubMedPubMedCentral

95.

Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan. China J Infect. 2020;81(1):e51–60. https://doi.org/10.1016/j.jinf.2020.04.012.CrossRefPubMed

96.

Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, et al. Next-generation sequencing of T and B Cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020. https://doi.org/10.1016/j.immuni.2020.06.024.CrossRefPubMedPubMedCentral

97.

Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020. https://doi.org/10.1038/s41586-020-2380-z.10.1038/s41586-020-2380-z.CrossRefPubMedPubMedCentral

98.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–6. https://doi.org/10.1038/s41591-020-0913-5.CrossRefPubMedPubMedCentral

99.

Seow J, Graham C, Merrick B, Acors S, Steel K, Hemmings O, et al. Longitudinal evaluationand declineof antibody responses in SARS-CoV-2 infection. Preprint medRxiv. 2020. https://doi.org/10.1101/2020.07.09.20148429.CrossRef

100.

Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020. https://doi.org/10.1038/s41591-020-0995-0.CrossRefPubMed

101.

Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthriti. Lancet. 2016;388(10055):1984. https://doi.org/10.1016/S0140-6736(16)30173-8.CrossRef

102.

Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465–70. https://doi.org/10.1038/s41584-020-0451-z.CrossRefPubMedPubMedCentral

103.

Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci. 2020;35(25):e237. https://doi.org/10.3346/jkms.2020.35.e237.CrossRefPubMedPubMedCentral

104.

Taylor PC. Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheumatol. 2020;16(9):477–8. https://doi.org/10.1038/s41584-020-0449-6.CrossRefPubMedPubMedCentral

105.

Mistry J, Sharif M, Prideaux A, Smith C, Sumbwanyambe M, Sibley M, et al. Use of rheumatoid arthritis impact of disease (RAID) in routine care; identification of DAS28 remission and unmet patient reported outcomes. Rheumatol Adv Pract. 2020;4(2):013. https://doi.org/10.1093/rap/rkaa013.CrossRef

106.

Ferreira RJO, Carvalho PD, Ndosi M, Duarte C, Chopra A, Murphy E, et al. Impact of patient’s global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the Meteor database. Arthritis Care Res (Hoboken). 2019;71(10):1317–25. https://doi.org/10.1002/acr.23866.CrossRef

107.

Bugatti S, De Stefano L, Favalli EG, Caporali R. Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217488 (annrheumdis-2020-217488).CrossRefPubMed

108.

Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(1878–8):8. https://doi.org/10.1016/S0140-6736(14)60128-8.CrossRef

109.

Holubar J, Le Quintrec M, Letaief H, Faillie JL, Pers YM, Jorgensen C. Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217919 (annrheumdis-2020-217919).CrossRefPubMed

110.

Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217787 (annrheumdis-2020-217787).CrossRefPubMed

111.

Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, et al. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217763 (annrheumdis-2020-217763).CrossRefPubMed

112.

Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41450.10.1002/art.41450.CrossRefPubMedPubMedCentral

113.

Gendebien Z, von Frenckell C, Ribbens C, André B, Thys M, Gangolf M, et al. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218244 (annrheumdis-2020-218244).CrossRefPubMed

114.

Wallace B, Washer L, Marder W, Kahlenberg JM. Patients with lupus with COVID-19: university of Michigan experience. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217794 (annrheumdis-2020-217794).CrossRefPubMed

115.

Sawalha AH, Zhao M, Coit P, Lu Q. Epigenetic dysregulation of ACE2 and interferon -regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol. 2020;215:108410. https://doi.org/10.1016/j.clim.2020.108410.CrossRefPubMedPubMedCentral

116.

Konig MF, Kim AH, Scheetz MH, Graef ER, Liew JW, Simard J, et al. COVID-19 global rheumatology alliance baseline. use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217690 (annrheumdis-2020-217690).CrossRefPubMed

117.

Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020;79(6):837–9. https://doi.org/10.1136/annrheumdis-2020-217566.CrossRefPubMed

118.

Horisberger A, Moi L, Ribi C, Comte D. Impact of COVID-19 pandemic on SLE: beyond the risk of infection. Lupus Sci Med. 2020;7(1):e000408. https://doi.org/10.1136/lupus-2020-000408.CrossRefPubMedPubMedCentral

119.

Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–39. https://doi.org/10.1016/S1474-4422(10)70094-6.CrossRefPubMed

120.

Castillo Álvarez F, López Pérez MÁ, Marzo Sola ME. Risk of SARS-CoV-2 infection and clinical outcomes in multiple sclerosis patients in La Rioja (Spain). Med Clin (Barc). 2020;S0025–7753(20):30444–9. https://doi.org/10.1016/j.medcli.2020.06.021.CrossRef

121.

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020;77(9):1079–88. https://doi.org/10.1001/jamaneurol.2020.2581.CrossRefPubMed

122.

Crescenzo F, Marastoni D, Bovo C, Calabrese M. Frequency and severity of COVID-19 in multiple sclerosis: a short single-site report from northern Italy. Mult Scler Relat Disord. 2020;44:102372. https://doi.org/10.1016/j.msard.2020.102372.CrossRefPubMedPubMedCentral

123.

Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020. https://doi.org/10.1038/s41586-020-2521-4.CrossRefPubMedPubMedCentral

124.

Cristiano E, Patrucco L, Rojas JI, Nuñez S. Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires. Argentina Mult Scler Relat Disord. 2020;44:102307. https://doi.org/10.1016/j.msard.2020.102307.CrossRefPubMed

125.

Fan M, Qiu W, Bu B, Xu Y, Yang H, Huang D, et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e787. https://doi.org/10.1212/NXI.0000000000000787.CrossRefPubMedPubMedCentral

126.

Aguirre C, Meca-Lallana V, Barrios-Blandino A, Del Río B, Vivancos J. Covid-19 in a patient with multiple sclerosis treated with natalizumab: may the blockade of integrins have a protective role? Mult Scler Relat Disord. 2020;44:102250. https://doi.org/10.1016/j.msard.2020.102250.CrossRefPubMedPubMedCentral

127.

Guevara C, Villa E, Rosas CS, Diaz V, Naves R. Treating patients with multiple sclerosis during the COVID-19 pandemic: assessing the expert recommendations. Mult Scler Relat Disord. 2020;43:102224. https://doi.org/10.1016/j.msard.2020.102224.CrossRefPubMedPubMedCentral

128.

Safavi F, Nourbakhsh B, Azimi AR. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020;43:102195. https://doi.org/10.1016/j.msard.2020.102195.CrossRefPubMedPubMedCentral

129.

Ghajarzadeh M, Mirmosayyeb O, Barzegar M, Nehzat N, Vaheb S, Shaygannejad V, et al. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic. Mult Scler Relat Disord. 2020;43:102222. https://doi.org/10.1016/j.msard.2020.102222.CrossRefPubMedPubMedCentral

130.

Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA. Anti-CD20 and Covid-19 in multiple sclerosis and related disorders: a case series of 60 patients from madrid. Spain Mult Scler Relat Disord. 2020;42:102185. https://doi.org/10.1016/j.msard.2020.102185.CrossRefPubMed

131.

Hodson R. Inflammatory bowel disease. Nature. 2016;540(7634):S97. https://doi.org/10.1038/540S9a.CrossRefPubMed

132.

Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. The incidence and outcomes of COVID -19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 2020. https://doi.org/10.1093/ibd/izaa170.CrossRefPubMed

133.

Grunert PC, Reuken PA, Stallhofer J, Teich N, Stallmach A. Inflammatory bowel disease in the COVID-19 pandemic-the patients’ perspective. J Crohns Colitis. 2020. https://doi.org/10.1093/ecco-jcc/jjaa126.CrossRefPubMed

134.

Zingone F, Savarino EV. Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. Lancet Gastroenterol Hepatol. 2020;5(6):525. https://doi.org/10.1016/S2468-1253(20)30085-6.CrossRefPubMedPubMedCentral

135.

Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the nancy and milan cohorts. Clin Gastroenterol Hepatol. 2020;18(9):2134–5. https://doi.org/10.1016/j.cgh.2020.04.071.CrossRefPubMedPubMedCentral

136.

Gubatan J, Levitte S, Balabanis T, Patel A, Sharma A, Habtezion A. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in northern california. Gastroenterology. 2020;S0016–5085(20):30601–6. https://doi.org/10.1053/j.gastro.2020.05.009.CrossRef

137.

Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. Risk of severe COVID-19 in patients with inflammatory bowel disease in united states. Multicent Res Netw Study Gastroenterol. 2020;S0016–5085(20):34755–7. https://doi.org/10.1053/j.gastro.2020.06.003.CrossRef

138.

Axelrad JE, Malter L, Hong S, Chang S, Bosworth B, Hudesman D. From the American epicenter: coronavirus disease 2019 in patients with inflammatory bowel disease in the New York city metropolitan area. Inflamm Bowel Dis. 2020. https://doi.org/10.1093/ibd/izaa162.CrossRefPubMed

139.

Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS, et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology. 2020;S0016–5085(20):34738–47. https://doi.org/10.1053/j.gastro.2020.05.066.CrossRef

140.

Krzysztof NJ, Christoffer LJ, Rahul K, Ricanek P, Jonas H, Jack S. Age, inflammation and disease location are critical determinants of intestinal expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in inflammatory bowel disease. Gastroenterology. 2020;S0016–5085(20):30653–63. https://doi.org/10.1053/j.gastro.2020.05.030.CrossRef

141.

Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, et al. British society of gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984–90. https://doi.org/10.1136/gutjnl-2020-321244.CrossRefPubMed

142.

Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159(1):350–7. https://doi.org/10.1053/j.gastro.2020.04.012.CrossRefPubMed

143.

Hanzel J, Ma C, Marshall JK, Feagan BG, Jairath V. Managing inflammatory bowel disease during COVID-19: summary of recommendations from gastrointestinal societies. Clin Gastroenterol Hepatol. 2020;18(9):2143–6. https://doi.org/10.1016/j.cgh.2020.04.033.CrossRefPubMedPubMedCentral

144.

Allocca M, Fiorino G, Furfaro F, Gilardi D, Radice S, D’Amico F, et al. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2020;18(8):1882–3. https://doi.org/10.1016/j.cgh.2020.04.028.CrossRefPubMedPubMedCentral

145.

Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464(7293):1293–300. https://doi.org/10.1038/nature08933.CrossRefPubMedPubMedCentral

146.

Vangoitsenhoven R, Martens PJ, van Nes F, Moyson C, Nobels F, Van Crombrugge P, et al. No evidence of increased hospitalization rate for COVID-19 in community-dwelling patients with type 1 diabetes. Diabetes Care. 2020. https://doi.org/10.2337/dc20-1246.CrossRefPubMedPubMedCentral

147.

Capaldo B, Annuzzi G, Creanza A, Giglio C, De Angelis R, Lupoli R, et al. Blood glucose control during lockdown for COVID-19: CGM metrics in italian adults with type 1 diabetes. Diabetes Care. 2020;43(8):e88–9. https://doi.org/10.2337/dc20-1127.CrossRefPubMedPubMedCentral

148.

Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic control in type 1 diabetes mellitus during COVID-19 quarantine and the role of in-home physical activity. Diabetes Technol Ther. 2020;22(6):462–7. https://doi.org/10.1089/dia.2020.0169.CrossRefPubMed

149.

Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U.S. Diabetes Care. 2020;43(8):e83–5. https://doi.org/10.2337/dc20-1088.CrossRefPubMedPubMedCentral

150.

Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99. https://doi.org/10.1016/S0140-6736(17)30933-9.CrossRefPubMed

151.

Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov NS, et al. Systemic sclerosis and the COVID-19 pandemic: world scleroderma foundation preliminary advice for patient management. Ann Rheum Dis. 2020;79(6):724–6. https://doi.org/10.1136/annrheumdis-2020-217407.CrossRefPubMed

152.

Minniti A, Maglione W, Pignataro F, Cappadona C, Caporali R, Del Papa N. Taking care of systemic sclerosis patients during COVID-19 pandemic: rethink the clinical activity. Clin Rheumatol. 2020;39(7):2063–5. https://doi.org/10.1007/s10067-020-05191-4.CrossRefPubMedPubMedCentral

153.

Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-217864.CrossRefPubMed

154.

Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15(1):489. https://doi.org/10.1007/s11882-014-0489-6.CrossRefPubMed

155.

Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int. 2019;2020:1–10. https://doi.org/10.1007/s00296-020-04635-z.CrossRef

156.

Lee JM, Lee SJ. Olfactory and gustatory dysfunction in a COVID-19 patient with ankylosing spondylitis treated with etanercept: case report. J Korean Med Sci. 2020;35(21):e201. https://doi.org/10.3346/jkms.2020.35.e201.CrossRefPubMedPubMedCentral

157.

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.1016/S0140-6736(14)61909-7.CrossRefPubMedCentral

158.

Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020. https://doi.org/10.1136/annrheumdis-2020-218946.CrossRefPubMed

159.

Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21(3):307–11. https://doi.org/10.1007/s40257-020-00514-2.CrossRefPubMed

160.

Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol. 2020;82(5):1217–8. https://doi.org/10.1016/j.jaad.2020.03.031.CrossRefPubMedPubMedCentral

161.

Gisondi P, Bellinato F, Chiricozzi A, Girolomoni G. The risk of COVID-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments. Vaccines (Basel). 2020;8(4):E728. https://doi.org/10.3390/vaccines8040728.CrossRef

162.

Annapureddy N, Nalleballe K, Onteddu SR, Sharma R, Sheng S, Kovvuru S, et al. Biologics in systemic autoimmune diseases during COVID-19 pandemic. Clin Rheumatol. 2020;39(12):3529–31. https://doi.org/10.1007/s10067-020-05439-z.CrossRefPubMed

163.

Ferri C, Giuggioli D, Raimondo V, L’Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195–204. https://doi.org/10.1007/s10067-020-05334-7.CrossRefPubMedPubMedCentral

164.

Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66. https://doi.org/10.1136/annrheumdis-2020-217871.CrossRefPubMed

165.

Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343. https://doi.org/10.1371/journal.pmed.0030343.CrossRefPubMedPubMedCentral

166.

Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–67. https://doi.org/10.1164/rccm.201706-1172OC.CrossRefPubMed

167.

WHO. COVID-19 Situation Report (2020). Weekly Operational Update on COVID-19. 4 Spetember 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/wou-4-september-2020 -approved. pdf?sfvrsn=91215c78_2 (assessed 7 September 2020).

168.

Dubbioso R, Nobile-Orazio E, Manganelli F, Santoro L, Briani C, Cocito D, et al. Dealing with immune-mediated neuropathies during COVID-19 outbreak: practical recommendations from the task force of the Italian society of neurology (SIN), the Italian society of clinical neurophysiology (SINC) and the Italian peripheral nervous system association (ASNP). Neurol Sci. 2020;41(6):1345–8. https://doi.org/10.1007/s10072-020-04448-9.CrossRefPubMed

169.

Ceribelli A, Motta F, De Santis M, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020;109:102442. https://doi.org/10.1016/j.jaut.2020.102442.CrossRefPubMedPubMedCentral

170.

Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785–91. https://doi.org/10.1136/ard.2010.128637.CrossRefPubMed

171.

Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord. 2020;45:102439. https://doi.org/10.1016/j.msard.2020.102439.CrossRefPubMedPubMedCentral

172.

Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer. 2020;136:4–6. https://doi.org/10.1016/j.ejca.2020.06.017.CrossRefPubMedPubMedCentral

173.

Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, et al. COVID-19 vaccine- readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020;202(2):149–61. https://doi.org/10.1111/cei.13495.CrossRefPubMedPubMedCentral

Titel: COVID-19 illness and autoimmune diseases: recent insights
verfasst von: Juan Li
Hong-Hui Liu
Xiao-Dong Yin
Cheng-Cheng Li
Jing Wang
Publikationsdatum: 28.02.2021
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Inflammation Research / Ausgabe 4/2021
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-021-01446-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Altered sensory innervation and pain hypersensitivity in a model of young painful arthritic joints: short- and long-term effects

Complement regulation in tenocytes under the influence of leukocytes in an indirect co-culture model

Propofol regulates activated macrophages metabolism through inhibition of ROS-mediated GLUT1 expression

Sepsis-induced myocardial dysfunction: the role of mitochondrial dysfunction

MicroRNA-301a-3p promotes diabetic retinopathy via regulation of six-transmembrane epithelial antigen of prostate 4